Oral prednisone reaches its peak plasma level in one to two hours. An intra-articular injection of triamcinolone may take several days before producing measurable relief. Between these two extremes, each route of glucocorticoid administration follows its own kinetics, and confusing blood absorption with clinical response remains the most common error in assessing the onset time of cortisone.
Pharmacokinetics versus clinical response: two timelines not to confuse
We regularly observe confusion between the peak plasma concentration and the moment when the patient perceives an improvement. Oral prednisone is rapidly absorbed, with a maximum concentration reached about one hour after ingestion. This pharmacokinetic data does not mean that inflammation decreases within an hour.
The anti-inflammatory effect of glucocorticoids involves a change in gene transcription in target cells. This genomic mechanism imposes a delay between the presence of the corticosteroid in the blood and the actual reduction of tissue inflammation.
For chronic inflammatory bowel diseases, patient associations like Crohn’s & Colitis UK indicate that oral corticosteroids generally take between one and four weeks to produce a tangible clinical effect, although some patients may experience earlier improvement.
This dual level of understanding (rapid pharmacokinetics, slow clinical response) applies to most routes of administration. Knowing how long it takes for cortisone to take effect therefore requires specifying what is meant by “effect”: presence in the blood or perceived relief.
Onset time of cortisone via intravenous and intramuscular routes
The intravenous (IV) route offers the most immediate bioavailability. IV methylprednisolone bolus, used in severe flares of autoimmune diseases or transplant rejections, reaches its target concentration almost instantly. The clinical anti-inflammatory effect follows in the hours after the infusion, making it the reference route in emergency situations.
The intramuscular (IM) route has a different profile. The injection of depot forms (cortisone acetate, for example) creates a deposit in the muscle. Absorption is gradual, spread over several days to weeks depending on the formulation. The peak plasma level after IM injection is later and flatter than in IV, which explains a prolonged clinical action time but an extended duration of effect.
We recommend not to directly compare these two injectable routes without considering the molecule used. IM dexamethasone acts faster than IM triamcinolone acetonide, due to their respective solubility.
Joint and peri-articular infiltration: a special case
Local corticosteroid infiltration (knee, shoulder, spine) aims for a concentrated topical effect. Triamcinolone acetonide or methylprednisolone acetate are the most commonly injected. The delay before relief varies significantly:
- A partial effect may appear within 24 to 48 hours after infiltration, related to the direct local action on synovial inflammatory cells
- The full benefit is often observed after a few days, sometimes up to a week, depending on the intensity of the pre-existing inflammation
- A transient worsening of pain in the first hours (crystal reaction) is common and should not be confused with treatment failure
The local duration of action of an infiltration far exceeds that of an oral intake, potentially extending over several weeks. This is precisely the advantage of this route: to concentrate the corticosteroid where it acts, limiting systemic exposure.
Factors modulating the delay in infiltration
The size of the joint, the volume of synovial fluid, and the presence of any effusion modify local kinetics. A highly inflamed joint “dilutes” the injected product and may delay the perceived effect. Ultrasound guidance improves placement accuracy and, consequently, the speed of response.
Cortisone in topical application and inhalation: often underestimated delays
Dermatocorticoids (betamethasone, clobetasol) applied to the skin act locally. Their penetration depends on the potency of the molecule, the vehicle (cream, ointment, lotion), and the treated area. A greasy ointment under occlusion penetrates much faster than a cream on dry skin exposed to air. Visible improvement (reduction of erythema, pruritus) generally occurs after a few days of regular application, rarely before 48 hours for inflammatory dermatoses like eczema.
Inhaled corticosteroids (budesonide, fluticasone) used in asthma and COPD have an even different profile. Their effect on bronchial hyperreactivity develops gradually over one to two weeks of daily use. They are not designed to relieve an acute attack, unlike short-acting bronchodilators.
Rectal route: a little-documented intermediary
Budesonide in suppository or rectal foam form, prescribed for inflammatory proctitis, acts locally with limited systemic absorption. The clinical response time usually occurs within the first week of treatment, with marked individual variability.
Power equivalences and impact on perceived delay
Comparing action times between molecules without considering their anti-inflammatory equivalence skews the analysis. Dexamethasone is about six to seven times more potent than prednisone on a weight basis. At equipotent doses, the pharmacokinetic delay remains similar for the same route, but the biological duration of action differs significantly:
- Prednisone has an intermediate biological half-life, suitable for daily intakes
- Dexamethasone has a long half-life, allowing for more spaced administrations
- Methylprednisolone falls between the two, with tissue affinity varying depending on the target
A patient who does not feel rapid improvement on oral prednisolone will not necessarily benefit from earlier relief by switching to oral dexamethasone. Changing the molecule alters the duration of anti-inflammatory coverage, not fundamentally the speed of effect onset.
The choice of administration route and molecule must therefore integrate both clinical urgency, the location of inflammation, and expected tolerance. The IV route remains the fastest in acute situations, the oral route the standard for prolonged treatments, and local routes (infiltration, topical, inhaled) prioritize concentration at the site of action at the cost of a longer onset time.